Evaluation of a commercial interferon-γ release assay for the detection of SARS-CoV-2 T-cell response after vaccination
(2023) Heliyon — Vol. 9, n° 6, p. e17186 [1-8] (2023)
Files
2023_Saad_Albichr_Heliyon.pdf
Open Access - Adobe PDF
- 1.12 MB
Details
- Authors
- Abstract
- (en) OBJECTIVE: Evidence regarding the role of cellular immunity in protecting against COVID-19 is emerging. To better assess immune status, simple and robust assays measuring specific T-cell responses associated with humoral responses are needed. We aimed to evaluate the Quan-T-Cell SARS-CoV-2 test for measuring cellular immune responses in vaccinated healthy and immunosuppressed subjects. METHODS: T-cell responses were assessed in healthy vaccinated and unvaccinated and unexposed healthcare workers to determine the sensitivity and specificity of the EUROIMMUN SARS-CoV-2 Quan-T-Cell IGRA test performed on vaccinated kidney transplant recipients (KTRs). RESULTS: The EUROIMMUN SARS-CoV-2 Quan-T-Cell IGRA test showed good sensitivity (87.2%) and specificity (92.3%) at the calculated 147 mIU/mL cutoff, with an 88.33% accuracy. In KTRs, specific cellular immunity was lower than the antibody response; however, those with a positive IGRA result produced as much IFN-γ as healthy individuals. CONCLUSIONS: The EUROIMMUN SARS-CoV-2 Quan-T-Cell IGRA test showed good sensitivity and specificity for the detection of specific T-cell responses against the SARS-CoV-2 spike protein. These results present an additional tool for better management of COVID-19, especially in vulnerable populations.
- Affiliations
Citations
Saad Albichr, I., Mzougui, S., Devresse, A., Georgery, H., Goffin, E., Kanaan, N., Yombi, J. C., Belkhir, L., De Greef, J., Scohy, A., Rodriguez-Villalobos, H., & Kabamba-Mukadi, B. (2023). Evaluation of a commercial interferon-γ release assay for the detection of SARS-CoV-2 T-cell response after vaccination. Heliyon, 9(6), e17186 [1-8]. https://doi.org/10.1016/j.heliyon.2023.e17186 (Original work published 2023)